Skip to Main Content Skip to Site Map Skip to Accessibility Statement

Recommend Technology Appraisals

Service notifications for recommended Technology Appraisals (TAs)

Technology Appraisals are listed below in alphanumerical order with links to further information on the NICE website.

TitleDescriptionDate addedDownload
TA837

Overview | Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | Guidance | NICE

18-01-2023 DownloadPreview
TA836

Overview | Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | Guidance | NICE

18-01-2023 DownloadPreview
TA835

Overview | Fostamatinib for treating refractory chronic immune thrombocytopenia | Guidance | NICE

18-01-2023 DownloadPreview
TA833

Overview | Zanubrutinib for treating Waldenstrom’s macroglobulinaemia | Guidance | NICE

18-01-2023 DownloadPreview
TA832

Overview | Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | Guidance | NICE

19-12-2022 DownloadPreview
TA830

Overview | Pembrolizumab for adjuvant treatment of renal cell carcinoma | Guidance | NICE

18-01-2023 DownloadPreview
TA829

Overview | Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy | Guidance | NICE

18-01-2023 DownloadPreview
TA828

Overview | Ozanimod for treating moderately to severely active ulcerative colitis | Guidance | NICE

18-01-2023 DownloadPreview
TA827

Overview | Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy | Guidance | NICE

18-01-2023 DownloadPreview
TA824

Overview | Dexamethasone intravitreal implant for treating diabetic macular oedema | Guidance | NICE

18-01-2023 DownloadPreview
TA823

Overview | Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | Guidance | NICE

18-01-2023 DownloadPreview
TA821

Overview | Avalglucosidase alfa for treating Pompe disease | Guidance | NICE

18-01-2023 DownloadPreview
TA813

Overview | Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | Guidance | NICE

18-01-2023 DownloadPreview
TA810

Overview | Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | Guidance | NICE

18-01-2023 DownloadPreview
TA809

Overview | Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease | Guidance | NICE

18-01-2023 DownloadPreview
TA808

Overview | Fenfluramine for treating seizures associated with Dravet syndrome | Guidance | NICE

18-01-2023 DownloadPreview
TA805

Overview | Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides | Guidance | NICE

19-12-2022 DownloadPreview
TA803

Overview | Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | Guidance | NICE

18-01-2023 DownloadPreview
TA802

Overview | Cemiplimab for treating advanced cutaneous squamous cell carcinoma | Guidance | NICE

18-01-2023 DownloadPreview
TA801

Overview | Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | Guidance | NICE

18-01-2023 DownloadPreview
1 2 3 20
NICE Ref Title Date Issued by HSCB
TA234 Abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor 05/01/2012
TA233 Golimumab for the treatment of ankylosing spondylitis 20/02/2012
TA232 Retigabine for the adjunctive treatment of partial onset seizures in epilepsy 05/01/2012
TA230 Bivalirudin for the treatment of ST-segment-elevation myocardial infarction 05/01/2012
TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion 05/01/2012
TA228 Bortezomib and thalidomide for the firstline treatment of multiple myeloma 05/01/2012
TA227 Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer 05/01/2012
TA226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma 05/01/2012
TA225 Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti- rheumatic drugs 20/02/2012
TA223 Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease 05/01/2012
TA222 Trabectedin for the treatment of relapsed ovarian cancer 05/01/2012
TA221 Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura 05/01/2012
TA220 Golimumab for the treatment of psoriatic arthritis 20/02/2012
TA216 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia 05/01/2012
TA215 Pazopanib for the first-line treatment of advanced renal cell carcinoma 05/01/2012
TA208 Trastuzumab for the treatment of HER2-positive metastatic gastric cancer 05/01/2012
TA203 Liraglutide for the treatment of type 2 diabetes mellitus 20/02/2012
TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C 05/01/2012
TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis 20/02/2012
TA198 Tocilizumab for the treatment of rheumatoid arthritis 05/01/2012
TA197 Dronedarone for the treatment of non-permanent atrial fibrillation 20/02/2012
TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor 05/01/2012
TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia 05/01/2012
TA190 Pemetrexed for the maintenance treatment of non-small-cell lung cancer 05/01/2012
TA188 Human growth hormone (somatropin) for the treatment of growth failure in children 05/01/2012
TA187 Infliximab (review) and adalimumab for the treatment of Crohn’s disease 05/01/2012
TA186 Certolizumab pegol for the treatment of rheumatoid arthritis 20/02/2012
TA169 Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma 05/01/2012
TA166 Cochlear implants for children and adults with severe to profound deafness 05/01/2012
TA98 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents 14/09/2016
TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C 05/01/2012
TA23 Temozolomide for the treatment of recurrent malignant gliomaC 02/08/2016
TA20 Riluzole for the treatment of Motor Neurone Disease 01/08/2016